Skip to main content

Intensity Therapeutics, Inc. (INTS)

Intensity Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: $9.00 - $11.00
Current IPO price range
Chart not available yet
Data will show when the stock starts trading.
Market Cap168.37M
Revenue (ttm)n/a
Net Income (ttm)-7.13M
Shares Out16.84M
EPS (ttm)-0.42
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About INTS

Intensity Therapeutics, Inc. is a clinical stage biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction leading to anti-cancer immune activation. Our new approach involves the direct injection into tumors of a unique product created from our DfuseRx℠ discovery platform. Our platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Amphiphilic molecules have two distinct components: one part is soluble in water and ...

IndustryBiotechnology
Founded2012
CEOLewis H. Bender
Employees8
Stock ExchangeNASDAQ
Ticker SymbolINTS
Full Company Profile

Financial Performance

Financial Statements

News

Intensity Therapeutics IPO Registration Document (S-1)

Intensity Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC